{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "potassium citrate",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "The objective of treatment with potassium citrate extended-release tablets is to provide potassium citrate extended-release tablets in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "Treatment should be discontinued if there is hyperkalemia, a significant rise in serum creatinine or a significant fall in blood hematocrit or hemoglobin. 2.2 Severe Hypocitraturia In patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (30 mEq two times/day or 20 mEq three times/day with meals or within 30 minutes after meals or bedtime snack).",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and effectiveness in children have not been established.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "No kidney-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for potassium citrate (Potassium Citrate), retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": false
      }
    ],
    "hepatic": [
      {
        "text": "No liver-impairment dose in this label. Not a statement that none is needed.",
        "source": "Read and found silent: the US FDA label for potassium citrate (Potassium Citrate), retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": false
      }
    ],
    "pregnancy": [
      {
        "text": "Animal reproduction studies have not been conducted.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "It is also not known whether potassium citrate extended-release tablets can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "Potassium citrate extended-release tablets should be given to a pregnant woman only if clearly needed.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "The normal potassium ion content of human milk is about 13 mEq/L.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "It is not known if potassium citrate extended-release tablets has an effect on this content.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      },
      {
        "text": "Potassium citrate extended-release tablets should be given to a woman who is breast feeding only if clearly needed.",
        "source": "US FDA label for potassium citrate (Potassium Citrate), section 'nursing mothers', retrieved 2026-08-29",
        "cached_file": "labels/potassium-citrate.json",
        "verbatim": true
      }
    ]
  }
}